Diabetic retinopathy and atherosclerosis: Is there a link?

Current Diabetes Reviews

Volumn 9, Issue 2, 2013, Pages 146-160

  Ellis, Thomas Phillip ^a   Choudhury, Ruhul Hassan ^a   Kaul, Kirti ^a   Chopra, Mohit ^a   Kohner, Eva Maria ^a   Tarr, Joanna Mary ^a   Chibber, Rakesh ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

Common pathological pathways; Diabetes; Diabetes accelerated cardiovascular diseases; Diabetic retinopathy; Therapeutics

Indexed keywords

ADVANCED GLYCATION END PRODUCT; APOLIPOPROTEIN E; CHOLESTEROL; COLONY STIMULATING FACTOR 1; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FOCAL ADHESION KINASE; GAMMA INTERFERON; GLUCOSAMINE; HEXOSAMINE; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN; MACROPHAGE MIGRATION INHIBITION FACTOR; PROTEIN KINASE C; SOMATOMEDIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CYTOKINE RELEASE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; ENZYME ACTIVATION; HUMAN; ISCHEMIC HEART DISEASE; LEUKOCYTE ADHERENCE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE; VISUAL IMPAIRMENT;

EID: 84877802316     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399811309020006     Document Type: Review

References (180)

1. WHO. Diabetes fact sheet 2011 [03/01/12]. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/index.html.
2. Fowler M. Microvascular and Macrovascular Complications of Diabetes. Clinical Diabetes. 2008; 26(2): 77-82.
3. Klein R, Klein BE, Moss SE, DeMets DL, Kaufman I, Voss PS. Prevalence of diabetes mellitus in southern Wisconsin. American journal of epidemiology. 1984 Jan; 119(1): 54-61. PubMed PMID: 6691336. eng.
4. Mannucci E, Monami M, Lamanna C, Adalsteinsson J. Postprandial glucose and diabetic complications: systematic review of observational studies. Acta Diabetologica. 2012; 49(4): 307-14. PMID: 22116350.eng.
5. Pang C, Jia L, Jiang S, et al. Determination of diabetic retinopathy prevalence and associated risk factors in Chinese diabetic and prediabetic subjects: Shanghai diabetic complications study. Diabetes/Metabolism Research and Reviews. 2012; 28(3): 276-83. PMID: 22139892.eng.
6. Klein R, Klein BE, Anderson S, Moss SE. Hypoglycemic therapy in patients diagnosed to have diabetes at 30 years of age or older. Journal of chronic diseases. 1984; 37(3): 159-65. PubMed PMID: 6365941. eng.
7. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984 Jan; 91(1): 1-9. PubMed PMID: 6709312. eng.
8. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA: the journal of the American Medical Association. 1979 May 11; 241(19): 2035-8. PubMed PMID: 430798. Epub 1979/05/11. eng.
9. Povel CM, Beulens JW, van der Schouw YT, et al. Metabolic Syndrome Model Definitions Predicting Type 2 Diabetes and Cardiovascular Disease. Diabetes Care. 2012 August 29, 2012. PMID: 22933442.eng.
10. Grundy SM. Cholesterol management in high-risk patients without heart disease. When is lipid-lowering medication warranted for primary prevention? Postgraduate medicine. 1998 Nov; 104(5): 117-20, 23-4, 29. PubMed PMID: 9823389. Epub 1998/11/21. eng.
11. Davis MD, Hiller R, Magli YL, et al. Prognosis for life in patients with diabetes: relation to severity of retinopathy. Transactions of the American Ophthalmological Society. 1979; 77: 144-70. PubMed PMID: 545824. PubMed Central PMCID: 1311699. Epub 1979/01/01. eng.
12. Rajala U, Pajunpaa H, Koskela P, et al. High cardiovascular disease mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes care. 2000 Jul; 23(7): 957-61. PubMed PMID: 10895846. Epub 2000/07/15. eng.
13. Klein R, Klein BE, Jensen SC, et al. Retinal emboli and stroke: the Beaver Dam Eye Study. Archives of ophthalmology. 1999 Aug; 117(8): 1063-8. PubMed PMID: 10448750. Epub 1999/08/17. eng.
14. Klein R, Marino EK, Kuller LH, et al. The relation of atherosclerotic cardiovascular disease to retinopathy in people with diabetes in the Cardiovascular Health Study. The British journal of ophthalmology. 2002 Jan; 86(1): 84-90. PubMed PMID: 11801510. PubMed Central PMCID: 1770969. Epub 2002/01/22. eng.
15. Juutilainen A, Lehto S, Ronnemaa T, et al. Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes care. 2007 Feb; 30(2): 292-9. PubMed PMID: 17259497. Epub 2007/01/30. eng.
16. Cheung N, Rogers S, Couper DJ, et al. Is diabetic retinopathy an independent risk factor for ischemic stroke? Stroke; a journal of cerebral circulation. 2007 Feb; 38(2): 398-401. PubMed PMID: 17194880. Epub 2006/12/30. eng.
17. Cheung N, Wang JJ, Klein R, et al. Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes care. 2007 Jul; 30(7): 1742-6. PubMed PMID: 17389333. Epub 2007/03/29. eng.
18. Cooper LS, Wong TY, Klein R, et al. Retinal microvascular abnormalities and MRI-defined subclinical cerebral infarction: the Atherosclerosis Risk in Communities Study. Stroke; a journal of cerebral circulation. 2006 Jan; 37(1): 82-6. PubMed PMID: 16306463. Epub 2005/11/25. eng.
19. Rema M, Mohan V, Deepa R, et al. Association of carotid intimamedia thickness and arterial stiffness with diabetic retinopathy: the Chennai Urban Rural Epidemiology Study (CURES-2). Diabetes care. 2004 Aug; 27(8): 1962-7. PubMed PMID: 15277424. Epub 2004/07/28. eng.
20. Almeida FK, Esteves JF, Gross JL, et al. Severe forms of retinopathy predict the presence of subclinical atherosclerosis in type 1 diabetes subjects. Arquivos brasileiros de cardiologia. 2011 Oct 21. PubMed PMID: 22011803. Epub 2011/10/21. Formas graves de retinopatia predizem aterosclerose subclinica em individuos com diabetes tipo 1. Eng
21. Frost D, Beischer W. Determinants of carotid artery wall thickening in young patients with type 1 diabetes mellitus. Diabetic Medicine. 1998 Oct; 15(10): 851-7. PubMed PMID: ISI: 000076287700009. English.
22. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005 Jun; 54(6): 1615-25. PubMed PMID: 15919781. eng.
23. Buse MG. Hexosamines, insulin resistance, and the complications of diabetes: current status. American journal of physiology. 2006 Jan; 290(1): E1-E8. PubMed PMID: 16339923. eng.
24. Branton MH, Kopp JB. TGF-beta and fibrosis. Microbes and infection/Institut Pasteur. 1999 Dec; 1(15): 1349-65. PubMed PMID: 10611762. eng.
25. Hirase K, Ikeda T, Sotozono C, Nishida K, Sawa H, Kinoshita S. Transforming growth factor beta2 in the vitreous in proliferative diabetic retinopathy. Archives of ophthalmology. 1998 Jun; 116(6): 738-41. PubMed PMID: 9639441. eng.
26. Grant PJ. The effects of highand medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes care. 1996 Jan; 19(1): 64-6. PubMed PMID: 8720537. eng.
27. James LR, Tang D, Ingram A, Ly H, et al. Flux through the hexosamine pathway is a determinant of nuclear factor kappaB-dependent promoter activation. Diabetes. 2002 Apr; 51(4): 1146-56. PubMed PMID: 11916938. eng.
28. Patel S, Santani D. Role of NF-kappa B in the pathogenesis of diabetes and its associated complications. Pharmacological Reports. 2009 Jul-Aug; 61(4): 595-603. PubMed PMID: ISI: 000271221700002. English.
29. Srinivasan V, Sandhya N, Sampathkumar R, et al. Balasubramanyam M. Glutamine fructose-6-phosphate amidotransferase (GFAT) gene expression and activity in patients with type 2 diabetes: inter-relationships with hyperglycaemia and oxidative stress. Clinical biochemistry. 2007 Sep; 40(13-14): 952-7. PubMed PMID: 17574229. eng.
30. Stenina OI, Krukovets I, Wang K, et al. Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat. Circulation. 2003 Jul 1; 107(25): 3209-15. PubMed PMID: 12810612. eng.
31. Raman P, Krukovets I, Marinic TE, Bornstein P, Stenina OI. Glycosylation mediates up-regulation of a potent antiangiogenic and proatherogenic protein, thrombospondin-1, by glucose in vascular smooth muscle cells. The Journal of biological chemistry. 2007 Feb 23; 282(8): 5704-14. PubMed PMID: 17178709. eng.
32. Duan W, Paka L, Pillarisetti S. Distinct effects of glucose and glucosamine on vascular endothelial and smooth muscle cells: evidence for a protective role for glucosamine in atherosclerosis. Cardiovascular diabetology. 2005; 4: 16. PubMed PMID: 16207378. eng.
33. Tannock LR, King VL. Proteoglycan mediated lipoprotein retention: a mechanism of diabetic atherosclerosis. Reviews in endocrine & metabolic disorders. 2008 Dec; 9(4): 289-300. PubMed PMID: 18584330. eng.
34. Conde-Knape K. Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications. Diabetes/metabolism research and reviews. 2001 Nov-Dec; 17(6): 412-21. PubMed PMID: 11757076. eng.
35. Wight TN, Potter-Perigo S, Aulinskas T. Proteoglycans and vascular cell proliferation. The American review of respiratory disease. 1989 Oct; 140(4): 1132-5. PubMed PMID: 2508521. eng.
36. Sage AT, Walter LA, Shi Y, Khan MI, Kaneto H, Capretta A, et al. Hexosamine biosynthesis pathway flux promotes endoplasmic reticulum stress, lipid accumulation, and inflammatory gene expression in hepatic cells. American journal of physiology. 2010 Mar; 298(3): E499-511. PubMed PMID: 19952345. eng.
37. Werstuck GH, Khan MI, Femia G, et al. Glucosamine-induced endoplasmic reticulum dysfunction is associated with accelerated atherosclerosis in a hyperglycemic mouse model. Diabetes. 2006 Jan; 55(1): 93-101. PubMed PMID: 16380481. eng.
38. Scull CM, Tabas I. Mechanisms of ER stress-induced apoptosis in atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology. 2011 Dec; 31(12): 2792-7. PubMed PMID: 22096099. eng.
39. Newton AC. Protein kinase C: structure, function, and regulation. The Journal of biological chemistry. 1995 Dec 1; 270(48): 28495-8. PubMed PMID: 7499357. Epub 1995/12/01. eng.
40. Hiramatsu Y, Sekiguchi N, Hayashi M, et al. Diacylglycerol production and protein kinase C activity are increased in a mouse model of diabetic embryopathy. Diabetes. 2002 Sep; 51(9): 2804-10. PubMed PMID: 12196474. Epub 2002/08/28. eng.
41. Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacological research: the official journal of the Italian Pharmacological Society. 2007 06/; 55(6): 498-510. PMID: 17574431.eng.
42. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998 June 1, 1998; 47(6): 859-66. PMID: 9604860.eng.
43. Bursell SE, Clermont AC, Kinsley BT, Simonson DC, Aiello LM, Wolpert HA. Retinal blood flow changes in patients with insulindependent diabetes mellitus and no diabetic retinopathy. Investigative ophthalmology & visual science. 1996 Apr; 37(5): 886-97. PubMed PMID: 8603873. Epub 1996/04/01. eng.
44. Bursell SE, Takagi C, Clermont AC, et al. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Investigative ophthalmology & visual science. 1997 Dec; 38(13): 2711-20. PubMed PMID: 9418723. Epub 1998/01/07. eng.
45. Salamanca DA, Khalil RA. Protein kinase C isoforms as specific targets for modulation of vascular smooth muscle function in hypertension. Biochemical pharmacology. 2005 Nov 25; 70(11): 1537-47. PubMed PMID: 16139252. PubMed Central PMCID: 1343531. Epub 2005/09/06. eng.
46. Tarr JM, Ding N, Kaul K, Antonell A, Pérez-Jurado LA, Chibber R. Cellular crosstalk between TNF-, NADPH oxidase, PKC 2, and C2GNT in human leukocytes. Cellular Signalling. 2011. PMID: 22182514.eng.
47. Aiello LP, Vignati L, Sheetz MJ, Zhi X, et al. Oral protein kinase c beta inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study 2. Retina (Philadelphia, Pa. 2011 Nov; 31(10): 2084-94. PubMed PMID: 21862954. eng.
48. Mehta NN, Sheetz M, Price K, et al. Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus. Cardiovascular drugs and therapy/sponsored by the International Society of Cardiovascular Pharmacotherapy. 2009 Feb; 23(1): 17-24. PubMed PMID: 18949545. PubMed Central PMCID: 3088108. Epub 2008/10/25. eng.
49. Yokota T, Ma RC, Park JY, et al. Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes. 2003 Mar; 52(3): 838-45. PubMed PMID: 12606528. Epub 2003/02/28. eng.
50. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991 Apr; 40(4): 405-12. PubMed PMID: 2010041. eng.
51. Halliwell B, Gutteridge JM. The antioxidants of human extracellular fluids. Arch Biochem Biophys. 1990 Jul; 280(1): 1-8. PubMed PMID: 2191627. eng.
52. Mates JM, Perez-Gomez C, Nunez de Castro I. Antioxidant enzymes and human diseases. Clinical biochemistry. 1999 Nov; 32(8): 595-603. PubMed PMID: 10638941. eng.
53. Kowluru RA. Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes. 2003 Mar; 52(3): 818-23. PubMed PMID: 12606525. eng.
54. Kowluru RA. Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Acta Diabetol. 2001 Dec; 38(4): 179-85. PubMed PMID: 11855796. eng.
55. Kowluru RA, Abbas SN. Diabetes-induced mitochondrial dysfunction in the retina. Investigative ophthalmology & visual science. 2003 Dec; 44(12): 5327-34. PubMed PMID: 14638734. eng.
56. Honing ML, Morrison PJ, Banga JD, et al. Nitric oxide availability in diabetes mellitus. Diabetes/metabolism reviews. 1998 Sep; 14(3): 241-9. PubMed PMID: 9816472. Epub 1998/11/17. eng.
57. Zheng L, Kern TS. Role of nitric oxide, superoxide, peroxynitrite and PARP in diabetic retinopathy. Front Biosci. 2009; 14: 3974-87. PubMed PMID: 19273327. eng.
58. Bowen PE, Borthakur G. Postprandial lipid oxidation and cardiovascular disease risk. Curr Atheroscler Rep. 2004 Nov; 6(6): 477-84. PubMed PMID: 15485594. eng.
59. Maejima K, Nakano S, Himeno M, et al. Increased basal levels of plasma nitric oxide in Type 2 diabetic subjects. Relationship to microvascular complications. Journal of diabetes and its complications. 2001 May-Jun; 15(3): 135-43. PubMed PMID: 11358682. Epub 2001/05/19. eng.
60. Napoli C, Ignarro LJ. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Archives of pharmacal research. 2009 Aug; 32(8): 1103-8. PubMed PMID: 19727602. Epub 2009/09/04. eng.
61. Hirafuji M, Tsunoda M, Machida T, et al. Reduced expressions of inducible nitric oxide synthase and cyclooxygenase-2 in vascular smooth muscle cells of stroke-prone spontaneously hypertensive rats. Life Sci. 2002 Jan 11; 70(8): 917-26. PubMed PMID: 11853230. eng.
62. Mohammad G, Kowluru RA. Novel role of mitochondrial matrix metalloproteinase-2 in the development of diabetic retinopathy. Investigative ophthalmology & visual science. 2011 May; 52(6): 3832-41. PubMed PMID: 21345984. eng.
63. Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am J Med. 2007 Sep; 120(9 Suppl 2): S12-7. PubMed PMID: 17826041. eng.
64. Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med. 2010 Mar 15; 48(6): 749-62. PubMed PMID: 20045723. eng.
65. Perrone L, Devi TS, Hosoya K, Terasaki T, Singh LP. Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J Cell Physiol. 2009 Oct; 221(1): 262-72. PubMed PMID: 19562690. eng.
66. Kowluru RA, Kern TS, Engerman RL, et al. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. III. Effects of antioxidants. Diabetes. 1996 Sep; 45(9): 1233-7. PubMed PMID: 8772728. eng.
67. Haskins K, Bradley B, Powers K, et al. Oxidative stress in type 1 diabetes. Ann N Y Acad Sci. 2003 Nov; 1005: 43-54. PubMed PMID: 14679039. eng.
68. Turan B. Role of antioxidants in redox regulation of diabetic cardiovascular complications. Curr Pharm Biotechnol. 2010 Dec; 11(8): 819-36. PubMed PMID: 20874678. eng.
69. Kowluru RA, Kennedy A. Therapeutic potential of anti-oxidants and diabetic retinopathy. Expert Opin Investig Drugs. 2001 Sep; 10(9): 1665-76. PubMed PMID: 11772276. eng.
70. Yang H, Jin X, Kei Lam CW, et al. Oxidative stress and diabetes mellitus. Clin Chem Lab Med. 2011 Nov; 49(11): 1773-82. PubMed PMID: 21810068. eng.
71. Clyne AM, Zhu H, Edelman ER. Elevated fibroblast growth factor-2 increases tumor necrosis factor-alpha induced endothelial cell death in high glucose. J Cell Physiol. 2008 Oct; 217(1): 86-92. PubMed PMID: 18446810. eng.
72. Lim HS, MacFadyen RJ, Lip GY. Diabetes mellitus, the reninangiotensin-aldosterone system, and the heart. Archives of internal medicine. 2004 Sep 13; 164(16): 1737-48. PubMed PMID: 15364666. Epub 2004/09/15. eng.
73. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998 Jan 3; 351(9095): 28-31. PubMed PMID: 9433426. eng.
74. Rosei EA, Rizzoni D, Muiesan ML, et al. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. Journal of hypertension. 2005 Feb; 23(2): 435-44. PubMed PMID: 15662233. eng.
75. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine. 2001 Sep 20; 345(12): 861-9. PubMed PMID: 11565518. eng.
76. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23; 359(9311): 995-1003. PubMed PMID: 11937178. eng.
77. Steckelings UM, Rompe F, Kaschina E, et al. The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundamental & clinical pharmacology. 2009 Dec; 23(6): 693-703. PubMed PMID: 19817870. Epub 2009/10/13. eng.
78. Yokota H, Nagaoka T, Tani T, et al. Higher levels of prorenin predict development of diabetic retinopathy in patients with type 2 diabetes. J Renin Angiotensin Aldosterone Syst. 2011 Sep; 12(3): 290-4. PubMed PMID: 21330419. Epub 2011/02/19. eng.
79. Wilkinson-Berka JL, Miller AG, Binger KJ. Prorenin and the (pro)renin receptor: recent advances and implications for retinal development and disease. Current opinion in nephrology and hypertension. 2011 Jan; 20(1): 69-76. PubMed PMID: 21099684. eng.
80. Nagai N, Izumi-Nagai K, Oike Y, et al. Suppression of diabetesinduced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Investigative ophthalmology & visual science. 2007 Sep; 48(9): 4342-50. PubMed PMID: 17724226. eng.
81. Ferrario CM. Contribution of angiotensin-(1-7) to cardiovascular physiology and pathology. Current hypertension reports. 2003 Apr; 5(2): 129-34. PubMed PMID: 12642012. eng.
82. Phipps JA, Clermont AC, Sinha S, Chilcote TJ, Bursell SE, Feener EP. Plasma kallikrein mediates angiotensin II type 1 receptorstimulated retinal vascular permeability. Hypertension. 2009 Feb; 53(2): 175-81. PubMed PMID: 19124682. Epub 2009/01/07. eng.
83. Rojas M, Zhang W, Lee DL, Romero MJ, et al. Role of IL-6 in angiotensin II-induced retinal vascular inflammation. Investigative ophthalmology & visual science. 2010 Mar; 51(3): 1709-18. PubMed PMID: 19834028. PubMed Central PMCID: 2868419. Epub 2009/10/17. eng.
84. Lemarie CA, Simeone SM, Nikonova A, et al. Aldosteroneinduced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res. 2009 Oct 23; 105(9): 852-9. PubMed PMID: 19762686. Epub 2009/09/19. eng.
85. Becher UM, Endtmann C, Tiyerili V, et al. Endothelial damage and regeneration: the role of the renin-angiotensin-aldosterone system. Current hypertension reports. 2011 Feb; 13(1): 86-92. PubMed PMID: 21108024. Epub 2010/11/26. eng.
86. Bader M. Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy. Annu Rev Pharmacol Toxicol. 2010; 50: 439-65. PubMed PMID: 20055710. Epub 2010/01/09. eng.
87. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. Journal of internal medicine. 2002 Feb; 251(2): 87-101. PubMed PMID: 11905595. Epub 2002/03/22. eng.
88. Hammes HP, Alt A, Niwa T, et al. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia. 1999 Jun; 42(6): 728-36. PubMed PMID: 10382593. Epub 1999/06/26. eng.
89. Endo M, Yanagisawa K, Tsuchida K, et al. Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy. Hormone and metabolic research = Hormonund Stoffwechselforschung = Hormones et metabolisme. 2001 May; 33(5): 317-22. PubMed PMID: 11440280. Epub 2001/07/07. eng.
90. Nin JW, Ferreira I, Schalkwijk CG, et al. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia. 2009 Apr; 52(4): 705-14. PubMed PMID: 19183936. Epub 2009/02/03. eng.
91. Nin JW, Jorsal A, Ferreira I, et al. Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes. 2010 Aug; 59(8): 2027-32. PubMed PMID: 20522598. PubMed Central PMCID: 2911054. Epub 2010/06/05. eng.
92. Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Experimental gerontology. 2011 Apr; 46(4): 217-24. PubMed PMID: 21111800. Epub 2010/11/30. eng.
93. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis. 2008 Jan; 196(1): 9-21. PubMed PMID: 17826783. Epub 2007/09/11. eng.
94. Falcone C, Emanuele E, D'Angelo A, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arteriosclerosis, thrombosis, and vascular biology. 2005 May; 25(5): 1032-7. PubMed PMID: 15731496. Epub 2005/02/26. eng.
95. Nilsson BO. Biological effects of aminoguanidine: an update. Inflammation research: official journal of the European Histamine Research Society [et al]. 1999 Oct; 48(10): 509-15. PubMed PMID: 10563466. Epub 1999/11/24. eng.
96. Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. American journal of nephrology. 2004 Jan-Feb; 24(1): 32-40. PubMed PMID: 14685005. Epub 2003/12/20. eng.
97. Watson AM, Soro-Paavonen A, Sheehy K, et al. Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia. 2011 Mar; 54(3): 681-9. PubMed PMID: 21161164. Epub 2010/12/17. eng.
98. Huang H, Gandhi JK, Zhong XF, et al. TNF alpha Is Required for Late BRB Breakdown in Diabetic Retinopathy, and Its Inhibition Prevents Leukostasis and Protects Vessels and Neurons from Apoptosis. Investigative ophthalmology & visual science. 2011 Mar; 52(3): 1336-44. PubMed PMID: ISI: 000288965300019. English.
99. Elkind MS, Rundek T, Sciacca RR, et al. Interleukin-2 levels are associated with carotid artery intima-media thickness. Atherosclerosis. 2005 May; 180(1): 181-7. PubMed PMID: 15823291. eng.
100. Upadhya S, Mooteri S, Peckham N, et al. Atherogenic effect of interleukin-2 and antiatherogenic effect of interleukin-2 antibody in apo-E-deficient mice. Angiology. 2004 May-Jun; 55(3): 289-94. PubMed PMID: 15156262. Epub 2004/05/25. eng.
101. Tenger C, Sundborger A, Jawien J, et al. IL-18 accelerates atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression independently of T cells. Arteriosclerosis, thrombosis, and vascular biology. 2005 Apr; 25(4): 791-6. PubMed PMID: 15604417. Epub 2004/12/18. eng.
102. Demircan N, Safran BG, Soylu M, et al. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye. 2006 Dec; 20(12): 1366-9. PubMed PMID: 16284605. Epub 2005/11/15. eng.
103. Johnsen-Soriano S, Sancho-Tello M, Arnal E, et al. IL-2 and IFN-gamma in the retina of diabetic rats. Archives of Clinical Experimental Opthalmology. 2010; 248: 985-90.
104. Wakabayashi Y, Usui Y, Okunuki Y, et al. Increases of vitreous monocyte chemotactic protein 1 and interleukin 8 levels in patients with concurrent hypertension and diabetic retinopathy. Retina (Philadelphia, Pa. 2011 Oct; 31(9): 1951-7. PubMed PMID: 21610567. Epub 2011/05/26. eng.
105. Khalifa RA. The Role of Interleukin 12 (IL-12), Interferon-Inducible Protein 10 (IP-10) and Interleukin 18 (IL-18) In the Angiogenic Activity of Diabetic Retinopathy. Research Journal of Medicine and Medical Sciences. 2009; 4(2): 510-4.
106. Kowluru RA, Odenbach S. Role of interleukin-1beta in the development of retinopathy in rats: effect of antioxidants. Investigative ophthalmology & visual science. 2004 Nov; 45(11): 4161-6. PubMed PMID: 15505070. Epub 2004/10/27. eng.
107. Schieffer B, Selle T, Hilfiker A, et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation. 2004 Nov 30; 110(22): 3493-500. PubMed PMID: 15557373. Epub 2004/11/24. eng.
108. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiological reviews. 2006 Apr; 86(2): 515-81. PubMed PMID: 16601268. Epub 2006/04/08. eng.
109. Yuuki T, Kanda T, Kimura Y, et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. Journal of diabetes and its complications. 2001 Sep-Oct; 15(5): 257-9. PubMed PMID: 11522500. Epub 2001/08/28. eng.
110. Mocan MC, Kadayifcilar S, Eldem B. Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy. Canadian journal of ophthalmology Journal canadien d'ophtalmologie. 2006 Dec; 41(6): 747-52. PubMed PMID: 17224958. Epub 2007/01/17. eng.
111. Gupta S, Pablo AM, Jiang X, Wang N, et al. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. The Journal of Clinical Investigation. 1997 Jun 1; 99(11): 2752-61. PubMed PMID: 9169506. PubMed Central PMCID: 508122. Epub 1997/06/01. eng.
112. Whitman SC, Ravisankar P, Elam H, et al. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/-mice. The American journal of pathology. 2000 Dec; 157(6): 1819-24. PubMed PMID: 11106554. PubMed Central PMCID: 1885762. Epub 2000/12/07. eng.
113. Panousis CG, Zuckerman SH. Interferon-gamma induces downregulation of Tangier disease gene (ATP-binding-cassette transporter 1) in macrophage-derived foam cells. Arteriosclerosis, thrombosis, and vascular biology. 2000 Jun; 20(6): 1565-71. PubMed PMID: 10845873. Epub 2000/06/10. eng.
114. Johnsen-Soriano S, Sancho-Tello M, Arnal E, et al. IL-2 and IFN-gamma in the retina of diabetic rats. Graefes Arch Clin Exp Ophthalmol. 2010 Jul; 248(7): 985-90. PubMed PMID: 20213480. eng.
115. Suzuki Y, Nakazawa M, Suzuki K, et al. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol. 2011 May; 55(3): 256-63. PubMed PMID: 21538000. eng.
116. Shaposhnik Z, Wang XP, Lusis AJ. Arterial colony stimulating factor-1 influences atherosclerotic lesions by regulating monocyte migration and apoptosis. Journal of Lipid Research. 2010 Jul; 51(7): 1962-70. PubMed PMID: ISI: 000278628700032. English.
117. Qiao JH, Tripathi J, Mishra NK, et al. Role of macrophage colony-stimulating factor in atherosclerosis - Studies of osteopetrotic mice. American Journal of Pathology. 1997 May; 150(5): 1687-99. PubMed PMID: ISI: A1997WX14100017. English.
118. Liu W, Xu GZ, Jiang CH, et al. Expression of Macrophage Colony-Stimulating Factor (M-CSF) and Its Receptor in Streptozotocin-Induced Diabetic Rats. Current eye research. 2009; 34(2): 123-33. PubMed PMID: ISI: 000263366800007. English.
119. Wautier MP, Boulanger E, Guillausseau PJ, et al. AGEs, macrophage colony stimulating factor and vascular adhesion molecule blood levels are increased in patients with diabetic microangiopathy. Thrombosis and haemostasis. 2004 May; 91(5): 879-85. PubMed PMID: ISI: 000221471700005. English.
120. Wu W, Wang M, Sun Z, Wang X, Miao J, Zheng Z. The predictive value of TNF-alpha and IL-6 and the incidence of macrovascular complications in patients with type 2 diabetes. Acta Diabetol. 2012 Feb; 49(1): 3-7. PubMed PMID: 20495833. eng.
121. Westermann D, Van Linthout S, Dhayat S, et al. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol. 2007 Nov; 102(6): 500-7. PubMed PMID: 17909696. eng.
122. Zorena K, Mysliwska J, Mysliwiec M, Balcerska A, Lipowski P, Raczynska K. Interleukin-12 and tumour necrosis factor-alpha equilibrium is a prerequisite for clinical course free from late complications in children with type 1 diabetes mellitus. Scand J Immunol. 2008 Feb; 67(2): 204-8. PubMed PMID: 18201373. Epub 2008/01/19. eng.
123. Tsilimbaris MK, Panagiotoglou TD, Charisis SK, Anastasakis A, Krikonis TS, Christodoulakis E. The use of intravitreal etanercept in diabetic macular oedema. Semin Ophthalmol. 2007 Apr-Jun; 22(2): 75-9. PubMed PMID: 17564925. eng.
124. Sfikakis PP, Grigoropoulos V, Emfietzoglou I, et al. Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. Diabetes care. 2010 Jul; 33(7): 1523-8. PubMed PMID: 20413522. eng.
125. Tan S, Cheng PW. Mucin biosynthesis: identification of the cisregulatory elements of human C2GnT-M gene. American journal of respiratory cell and molecular biology. 2007 Jun; 36(6): 737-45. PubMed PMID: 17303715. PubMed Central PMCID: 1899342. Epub 2007/02/17. eng.
126. Brockhausen I. Pathways of O-glycan biosynthesis in cancer cells. Biochimica et biophysica acta. 1999 Dec 6; 1473(1): 67-95. PubMed PMID: 10580130. Epub 1999/12/02. eng.
127. Kumar R, Camphausen RT, Sullivan FX, et al. Core2 beta-1,6-Nacetylglucosaminyltransferase enzyme activity is critical for Pselectin glycoprotein ligand-1 binding to P-selectin. Blood. 1996 Nov 15; 88(10): 3872-9. PubMed PMID: 8916952. Epub 1996/11/15. eng.
128. Sako D, Chang XJ, Barone KM, et al. Expression cloning of a functional glycoprotein ligand for P-selectin. Cell. 1993 Dec 17; 75(6): 1179-86. PubMed PMID: 7505206. Epub 1993/12/17. eng.
129. Moore KL, Eaton SF, Lyons DE, Lichenstein HS, Cummings RD, McEver RP. The P-selectin glycoprotein ligand from human neutrophils displays sialylated, fucosylated, O-linked poly-Nacetyllactosamine. The Journal of biological chemistry. 1994 Sep 16; 269(37): 23318-27. PubMed PMID: 7521878. Epub 1994/09/16. eng.
130. Chibber R, Ben-Mahmud BM, Coppini D, et al. Activity of the glycosylating enzyme, core 2 GlcNAc (beta1,6) transferase, is higher in polymorphonuclear leukocytes from diabetic patients compared with age-matched control subjects: relevance to capillary occlusion in diabetic retinopathy. Diabetes. 2000 Oct; 49(10): 1724-30. PubMed PMID: 11016457. Epub 2000/10/04. eng.
131. Ben-Mahmud BM, Chan WH, Abdulahad RM, et al. Clinical validation of a link between TNF-alpha and the glycosylation enzyme core 2 GlcNAc-T and the relationship of this link to diabetic retinopathy. Diabetologia. 2006 Sep; 49(9): 2185-91. PubMed PMID: 16832663. Epub 2006/07/13. eng.
132. Nishio Y, Warren CE, Buczek-Thomas JA, et al. Identification and characterization of a gene regulating enzymatic glycosylation which is induced by diabetes and hyperglycemia specifically in rat cardiac tissue. The Journal of Clinical Investigation. 1995 Oct; 96(4): 1759-67. PubMed PMID: 7560067. PubMed Central PMCID: 366652. Epub 1995/10/01. eng.
133. Wang H, Zhang W, Tang R, et al. Core2 1-6-N-glucosaminyltransferase-I deficiency protects injured arteries from neointima formation in ApoE-deficient mice. Arteriosclerosis, thrombosis, and vascular biology. 2009 Jul; 29(7): 1053-9. PubMed PMID: 19372458. PubMed Central PMCID: 2735567. Epub 2009/04/18. eng.
134. Wang H, Tang R, Zhang WY, et al. Core2 1-6-N-Glucosaminyltransferase-I Is Crucial for the Formation of Atherosclerotic Lesions in Apolipoprotein E-Deficient Mice. Arteriosclerosis Thrombosis and Vascular Biology. 2009 Feb; 29(2): 180-U86. PubMed PMID: ISI: 000262602200007. English.
135. Papadopoulou C, Corrigall V, Taylor PR, et al. The role of the chemokines MCP-1, GRO-alpha, IL-8 and their receptors in the adhesion of monocytic cells to human atherosclerotic plaques. Cytokine. 2008 Aug; 43(2): 181-6. PubMed PMID: ISI: 000258893600013. English.
136. Miyamoto K, Hiroshiba N, Tsujikawa A, et al. In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Investigative ophthalmology & visual science. 1998 Oct; 39(11): 2190-4. PubMed PMID: 9761301. Epub 1998/10/07. eng.
137. OBrien KD, McDonald TO, Chait A, et al. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation. 1996 Feb 15; 93(4): 672-82. PubMed PMID: ISI: A1996TV05300009. English.
138. Knudsen ST, Foss CH, Poulsen PL, et al. E-selectin-inducing activity in plasma from type 2 diabetic patients with maculopathy. American Journal of Physiology-Endocrinology and Metabolism. 2003 Jan; 284(1): E1-E6. PubMed PMID: ISI: 000179858100001. English.
139. Chavakis E, Choi EY, Chavakis T. Novel aspects in the regulation of the leukocyte adhesion cascade. Thrombosis and haemostasis. 2009 Aug; 102(2): 191-7. PubMed PMID: 19652868. PubMed Central PMCID: 2722029. Epub 2009/08/05. eng.
140. Booth G, Stalker TJ, Lefer AM, et al. Mechanisms of amelioration of glucose-induced endothelial dysfunction following inhibition of protein kinase C in vivo. Diabetes. 2002 May; 51(5): 1556-64. PubMed PMID: 11978656. Epub 2002/04/30. eng.
141. Gareus R, Kotsaki E, Xanthoulea S, et al. Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis. Cell metabolism. 2008 Nov; 8(5): 372-83. PubMed PMID: 19046569. Epub 2008/12/03. eng.
142. Hajra L, Evans AI, Chen M, Hyduk SJ, Collins T, Cybulsky MI. The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proceedings of the National Academy of Sciences of the United States of America. 2000 Aug 1; 97(16): 9052-7. PubMed PMID: 10922059. PubMed Central PMCID: 16820. Epub 2000/08/02. eng.
143. Morigi M, Angioletti S, Imberti B, et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kappa B-dependent fashion. Journal of Clinical Investigation. 1998 May 1; 101(9): 1905-15. PubMed PMID: ISI: 000073630700014. English.
144. Rudofsky G, Reismann P, Schiekofer S, et al. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappa B activation in PBMCs. Hormone and Metabolic Research. 2004 Sep; 36(9): 630-8. PubMed PMID: ISI: 000224765200008. English.
145. Nowak M, Wielkoszynski T, Marek B, et al. Blood serum levels of vascular cell adhesion molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1) and endothelial leucocyte adhesion molecule-1 (ELAM-1) in diabetic retinopathy. Clinical and experimental medicine. 2008 Sep; 8(3): 159-64. PubMed PMID: 18791689. Epub 2008/09/16. eng.
146. Barile GR, Chang SS, Park LS, et al. Soluble cellular adhesion molecules in proliferative vitreoretinopathy and proliferative diabetic retinopathy. Current eye research. 1999 Sep; 19(3): 219-27. PubMed PMID: 10487959. Epub 1999/09/17. eng.
147. Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proceedings of the National Academy of Sciences of the United States of America. 1999 Sep 14; 96(19): 10836-41. PubMed PMID: ISI: 000082574100058. English.
148. Rubio-Guerra AF, Vargas-Robles H, Nuevo JJL, et al. Correlation between Circulating Adhesion Molecule Levels and Albuminuria in Type-2 Diabetic Hypertensive Patients. Kidney & Blood Pressure Research. 2009; 32(2): 106-9. PubMed PMID: ISI: 000267091300006. English.
149. Hirai FE, Tielsch JM, Klein BE, et al. Ten-year change in visionrelated quality of life in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology. 2011 Feb; 118(2): 353-8. PubMed PMID: 20884058. eng.
150. Nigro J, Osman N, Dart AM, et al. Insulin resistance and atherosclerosis. Endocrine reviews. 2006 May; 27(3): 242-59. PubMed PMID: 16492903. eng.
151. Iida KT, Shimano H, Kawakami Y, et al. Insulin up-regulates tumor necrosis factor-alpha production in macrophages through an extracellular-regulated kinase-dependent pathway. The Journal of biological chemistry. 2001 Aug 31; 276(35): 32531-7. PubMed PMID: 11443108. eng.
152. Chantelau E, Kimmerle R, Meyer-Schwickerath R. Insulin, insulin analogues and diabetic retinopathy. Archives of physiology and biochemistry. 2008 Feb; 114(1): 54-62. PubMed PMID: 18465359. eng.
153. Savage PJ, Saad MF. Insulin and atherosclerosis: villain, accomplice, or innocent bystander? British heart journal. 1993 Jun; 69(6): 473-5. PubMed PMID: 8343309. eng.
154. Walcher D, Aleksic M, Jerg V, Hombach V, et al. C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase. Diabetes. 2004 Jul; 53(7): 1664-70. PubMed PMID: 15220188. eng.
155. Laakso M. Cardiovascular Disease in Type 2 Diabetes From Population to Man to Mechanisms. Diabetes Care. 2010 February 1, 2010; 33(2): 442-9.
156. Morsi WG, Shaker OG, Ismail EF, et al. HO-1 and VGEF gene expression in human arteries with advanced atherosclerosis. Clinical biochemistry. 2006 Nov; 39(11): 1057-62. PubMed PMID: 16999951. eng.
157. Boulton M, Foreman D, Williams G, et al. VEGF localisation in diabetic retinopathy. The British journal of ophthalmology. 1998 May; 82(5): 561-8. PubMed PMID: 9713066. eng.
158. Lutty GA, McLeod DS, Merges C, et al. Localization of vascular endothelial growth factor in human retina and choroid. Archives of ophthalmology. 1996 Aug; 114(8): 971-7. PubMed PMID: 8694733. eng.
159. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Investigative ophthalmology & visual science. 2001 Sep; 42(10): 2408-13. PubMed PMID: 11527957. eng.
160. Simo R, Hernandez C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia. 2008 Sep; 51(9): 1574-80. PubMed PMID: 18404258. eng.
161. Rudge JS, Thurston G, Davis S, et al. VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGenebased discovery of the next generation of angiogenesis targets. Cold Spring Harbor symposia on quantitative biology. 2005; 70: 411-8. PubMed PMID: 16869778. eng.
162. Kaiser PK. Vascular endothelial growth factor Trap-Eye for diabetic macular oedema. The British journal of ophthalmology. 2009 Feb; 93(2): 135-6. PubMed PMID: 19174397. eng.
163. Raj T, Kanellakis P, Pomilio G, et al. Inhibition of fibroblast growth factor receptor signaling attenuates atherosclerosis in apolipoprotein E-deficient mice. Arteriosclerosis, thrombosis, and vascular biology. 2006 Aug; 26(8): 1845-51. PubMed PMID: 16709940. eng.
164. Rauch BH, Millette E, Kenagy RD, et al. Thrombin-and factor Xa-induced DNA synthesis is mediated by transactivation of fibroblast growth factor receptor-1 in human vascular smooth muscle cells. Circ Res. 2004 Feb 20; 94(3): 340-5. PubMed PMID: 14670838. eng.
165. Sivalingam A, Kenney J, Brown GC, et al. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Archives of ophthalmology. 1990 Jun; 108(6): 869-72. PubMed PMID: 1693499. eng.
166. Morss AS, Edelman ER. Glucose modulates basement membrane fibroblast growth factor-2 via alterations in endothelial cell permeability. The Journal of biological chemistry. 2007 May 11; 282(19): 14635-44. PubMed PMID: 17327226. eng.
167. Barrett-Connor E, Grundy SM, Holdbrook MJ. Plasma lipids and diabetes mellitus in an adult community. American journal of epidemiology. 1982 May; 115(5): 657-63. PubMed PMID: 7081197. Epub 1982/05/01. eng.
168. Ginsberg HN. Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes. 1996 Jul; 45 Suppl 3: S27-30. PubMed PMID: 8674885. eng.
169. Goldberg RB, Capuzzi D. Lipid disorders in type 1 and type 2 diabetes. Clinics in laboratory medicine. 2001 Mar; 21(1): 147-72, vii. PubMed PMID: 11321932. eng.
170. Kunjathoor VV, Febbraio M, Podrez EA, et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. The Journal of biological chemistry. 2002 Dec 20; 277(51): 49982-8. PubMed PMID: 12376530. Epub 2002/10/12. eng.
171. Li AC, Glass CK. PPAR-and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. Journal of Lipid Research. 2004 Dec; 45(12): 2161-73. PubMed PMID: ISI: 000225602100001. English.
172. Park YM, Febbraio M, Silverstein RL. CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima. The Journal of Clinical Investigation. 2009 Jan; 119(1): 136-45. PubMed PMID: 19065049. PubMed Central PMCID: 2613464. Epub 2008/12/10. eng.
173. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nature Medicine. 2002 Nov; 8(11): 1235-42. PubMed PMID: ISI: 000179221200028. English.
174. Wu M, Chen Y, Wilson K, et al. Intraretinal leakage and oxidation of LDL in diabetic retinopathy. Investigative ophthalmology & visual science. 2008 Jun; 49(6): 2679-85. PubMed PMID: 18362112. Epub 2008/03/26. eng.
175. Sata M, Walsh K. Oxidized LDL activates fas-mediated endothelial cell apoptosis. The Journal of Clinical Investigation. 1998 Nov 1; 102(9): 1682-9. PubMed PMID: 9802882. PubMed Central PMCID: 509116. Epub 1998/11/05. eng.
176. Chen L, Yang G, Zhang X, et al. Induction of MIF expression by oxidized LDL via activation of NF-kappaB in vascular smooth muscle cells. Atherosclerosis. 2009 Dec; 207(2): 428-33. PubMed PMID: 19640536. Epub 2009/07/31. eng.
177. Chavakis E, Dernbach E, Hermann C, et al. Oxidized LDL inhibits vascular endothelial growth factor-induced endothelial cell migration by an inhibitory effect on the Akt/endothelial nitric oxide synthase pathway. Circulation. 2001 Apr 24; 103(16): 2102-7. PubMed PMID: ISI: 000168383300023. English.
178. Fredenrich A, Bayer P. Reverse cholesterol transport, high density lipoproteins and HDL cholesterol: recent data. Diabetes & Metabolism. 2003 Jun; 29(3): 201-5. PubMed PMID: ISI: 000184152100002. English.
179. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Medicine. 2001 Jan; 7(1): 53-8. PubMed PMID: 11135616. Epub 2001/01/03. eng.
180. Ren J, Jin W, Chen H. oxHDL decreases the expression of CD36 on human macrophages through PPARgamma and p38 MAP kinase dependent mechanisms. Molecular and cellular biochemistry. 2010 Sep; 342(1-2): 171-81. PubMed PMID: 20458524. Epub 2010/05/12. eng.